Paving a path toward opioid-free pain relief for the patients who need it most.

Our Strategy

Many people in pain have been left behind by the current standard of care. Treatment options are limited, which forces many to resort to opioid therapy, use drugs with unknown safety profiles for their conditions, or live in pain.

Our unique approach to acute and chronic pain in select conditions is rooted in the mechanism of action, documented efficacy in painful inflammatory conditions, and clinically differentiated profile of COX-2 selective NSAIDs.

Our lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic

Our approach to indication selection

Coxib chart

Partner with us

If you are as dedicated to serving those in pain as we are, let's join forces.